Abstract
Purpose::
To test the varying doses of intravitreal bevacizumab in patients with retinal neovascularization (NVE or NVD) secondary to diabetes mellitus in a interventional, consecutive, retrospective case series. The study was conducted in compliance with the Declaration of Helsinki.
Methods::
Twenty eyes of 19 patients with retinal neovascularization due to Proliferative Diabetic Retinopathy. Patients were divided in four groups received intravitreal bevacizumab (150 µg -1.25 mg). First group received 1.25 mg, second group 600 µg, third group 300 µg and fourth group 150 µg in a single intravitreal injection under sterile conditions. Ophthalmic evaluations included non-standardized Snellen visual acuity (VA), complete ophthalmic examination, optical coherence tomography and mostly fluorescein angiography to identify the presence of NVE or NVD and the amount of leakage.
Results::
No significant ocular or systemic adverse effects were noted. Complete resolution of angiographic leakage of neovascularization was noted in all eyes from the first week.
Conclusions::
Short-term results suggest that intravitreal bevacizumab even in lower doses than standard is effective in reversing temporarily NVE or NVD in diabetics.
Keywords: diabetic retinopathy • neovascularization